|
|
|
|
|
(State or other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
| Item 2.02. |
Results of Operations and Financial Condition.
|
| Item 7.01. |
Regulation FD Disclosure.
|
| Item 9.01. |
Financial Statements and Exhibits.
|
| (d) |
Exhibits
|
|
Press Release dated October 26, 2022
|
||
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
|
TURNING POINT BRANDS, INC.
|
|||
|
Dated: October 26, 2022
|
By:
|
/s/ Brittani N. Cushman
|
|
|
Brittani N. Cushman
|
|||
|
Senior Vice President, General Counsel and Secretary
|
|||
| • |
Net sales decreased 1.9% to $107.8 million
|
| o |
Combined net sales increased 17.7% for Zig-Zag and Stoker’s Products (increased 23.3% and 10.0%, respectively)
|
| o |
NewGen net sales declined by 40.3% (declined 3.9% sequentially)
|
| • |
Gross profit decreased 2.9% to $52.7 million
|
| • |
Net income decreased 14.3% to $11.5 million
|
| • |
Adjusted EBITDA decreased 6.7% to $24.5 million (see Schedule A for a reconciliation to net income)
|
| • |
Diluted EPS of $0.60 and Adjusted Diluted EPS of $0.72 compared to $0.65 and $0.72 in the same period one year ago, respectively (see Schedule B for a reconciliation to Diluted EPS)
|
| • |
$0.4 million of ERP / CRM scoping expenses and duplicative system costs compared to none in the previous year
|
| • |
$1.4 million of stock options, restricted stock and incentive expense compared to $1.8 million in the year-ago period
|
| • |
$1.2 million of FDA PMTA-related expenses compared to $1.0 million in the year-ago period
|
| • |
$2.3 million Turning Point Brands Canada compared to $1.5 in the year-ago period
|
| • |
Zig-Zag Products sales of $186 to $191 million (compared to previous outlook of $193 to $200 million)
|
| • |
Stoker's Products sales of $128 to $132 million (compared to previous outlook of $127 to $133 million)
|
| • |
Consolidated adjusted EBITDA of $96 to $99 million (compared to previous outlook of $97 to $103 million)
|
|
Three Months Ended September 30,
|
||||||||
|
2022
|
2021
|
|||||||
|
Net sales
|
$
|
107,802
|
$
|
109,904
|
||||
|
Cost of sales
|
55,090
|
55,635
|
||||||
|
Gross profit
|
52,712
|
54,269
|
||||||
|
Selling, general, and administrative expenses
|
32,891
|
31,894
|
||||||
|
Operating income
|
19,821
|
22,375
|
||||||
|
Interest expense, net
|
4,802
|
5,397
|
||||||
|
Investment income
|
(75
|
)
|
(157
|
)
|
||||
|
Gain on extinguishment of debt
|
-
|
(375
|
)
|
|||||
|
Income before income taxes
|
15,094
|
17,510
|
||||||
|
Income tax expense
|
3,797
|
4,073
|
||||||
|
Consolidated net income
|
11,297
|
13,437
|
||||||
|
Net loss attributable to non-controlling interest
|
(239
|
)
|
(31
|
)
|
||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
11,536
|
$
|
13,468
|
||||
|
Basic income per common share:
|
||||||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
0.65
|
$
|
0.71
|
||||
|
Diluted income per common share:
|
||||||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
0.60
|
$
|
0.65
|
||||
|
Weighted average common shares outstanding:
|
||||||||
|
Basic
|
17,749,294
|
18,897,974
|
||||||
|
Diluted
|
21,102,006
|
22,364,807
|
||||||
|
Supplemental disclosures of statements of income information:
|
||||||||
|
Excise tax expense
|
$
|
5,747
|
$
|
6,040
|
||||
|
FDA fees
|
$
|
170
|
$
|
163
|
||||
|
ASSETS
|
(unaudited)
September 30,
2022
|
December 31,
2021
|
||||||
|
Current assets:
|
||||||||
|
Cash
|
$
|
105,672
|
$
|
128,320
|
||||
|
Accounts receivable, net of allowances of $107 in 2022 and $262 in 2021
|
11,453
|
6,496
|
||||||
|
Inventories
|
113,928
|
87,607
|
||||||
|
Other current assets
|
24,729
|
26,746
|
||||||
|
Total current assets
|
255,782
|
249,169
|
||||||
|
Property, plant, and equipment, net
|
22,512
|
18,650
|
||||||
|
Deferred income taxes
|
2,795
|
1,363
|
||||||
|
Right of use assets
|
13,185
|
15,053
|
||||||
|
Deferred financing costs, net
|
309
|
388
|
||||||
|
Goodwill
|
162,120
|
162,333
|
||||||
|
Other intangible assets, net
|
86,112
|
87,485
|
||||||
|
Master Settlement Agreement (MSA) escrow deposits
|
27,845
|
31,720
|
||||||
|
Other assets
|
29,129
|
35,399
|
||||||
|
Total assets
|
$
|
599,789
|
$
|
601,560
|
||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
9,247
|
$
|
7,361
|
||||
|
Accrued liabilities
|
32,613
|
32,937
|
||||||
|
Other current liabilities
|
21
|
38
|
||||||
|
Total current liabilities
|
41,881
|
40,336
|
||||||
|
Notes payable and long-term debt
|
416,029
|
414,172
|
||||||
|
Lease liabilities
|
11,299
|
13,336
|
||||||
|
Total liabilities
|
469,209
|
467,844
|
||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders' equity:
|
||||||||
|
Preferred stock; $0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-
|
-
|
-
|
||||||
|
Common stock, voting, $0.01 par value; authorized shares, 190,000,000; 19,801,623 issued shares
and 17,587,122 outstanding shares at September 30, 2022, and 19,690,884 issued shares and
18,395,476 outstanding shares at December 31, 2021
|
198
|
197
|
||||||
|
Common stock, nonvoting, $0.01 par value; authorized shares, 10,000,000;
issued and outstanding shares -0-
|
-
|
-
|
||||||
|
Additional paid-in capital
|
112,034
|
108,811
|
||||||
|
Cost of repurchased common stock (2,214,501 shares at September 30, 2022 and 1,295,408 shares at December 31, 2021)
|
(75,901
|
)
|
(48,869
|
)
|
||||
|
Accumulated other comprehensive loss
|
(3,424
|
)
|
(195
|
)
|
||||
|
Accumulated earnings
|
96,088
|
71,460
|
||||||
|
Non-controlling interest
|
1,585
|
2,312
|
||||||
|
Total stockholders' equity
|
130,580
|
133,716
|
||||||
|
Total liabilities and stockholders' equity
|
$
|
599,789
|
$
|
601,560
|
||||
|
Nine Months Ended September 30,
|
||||||||
|
2022
|
2021
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Consolidated net income
|
$
|
27,274
|
$
|
40,007
|
||||
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
|
Loss on extinguishment of debt
|
-
|
5,331
|
||||||
|
Gain on sale of property, plant, and equipment
|
(8
|
)
|
(2
|
)
|
||||
|
Depreciation expense
|
2,611
|
2,313
|
||||||
|
Amortization of other intangible assets
|
1,373
|
1,431
|
||||||
|
Amortization of deferred financing costs
|
1,936
|
1,895
|
||||||
|
Deferred income tax (benefit) expense
|
(431
|
)
|
1,528
|
|||||
|
Stock compensation expense
|
4,103
|
6,015
|
||||||
|
Noncash lease income
|
-
|
(49
|
)
|
|||||
|
Loss (gain) on investments
|
6,244
|
(144
|
)
|
|||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable
|
(5,030
|
)
|
1,324
|
|||||
|
Inventories
|
(26,467
|
)
|
(10,970
|
)
|
||||
|
Other current assets
|
1,891
|
(491
|
)
|
|||||
|
Other assets
|
1,211
|
685
|
||||||
|
Accounts payable
|
2,074
|
3,488
|
||||||
|
Accrued liabilities and other
|
(392
|
)
|
(2,796
|
)
|
||||
|
Net cash provided by operating activities
|
$
|
16,389
|
$
|
49,565
|
||||
|
Cash flows from investing activities:
|
||||||||
|
Capital expenditures
|
$
|
(6,662
|
)
|
$
|
(4,391
|
)
|
||
|
Acquisitions, net of cash acquired
|
-
|
(16,416
|
)
|
|||||
|
Payments for investments
|
(1,000
|
)
|
(16,657
|
)
|
||||
|
Restricted cash, MSA escrow deposits
|
(10,169
|
)
|
(14,783
|
)
|
||||
|
Proceeds on the sale of property, plant and equipment
|
63
|
2
|
||||||
|
Net cash used in investing activities
|
$
|
(17,768
|
)
|
$
|
(52,245
|
)
|
||
|
Cash flows from financing activities:
|
||||||||
|
Proceeds from Senior Secured Notes
|
$
|
-
|
$
|
250,000
|
||||
|
Payments of 2018 first lien term loan
|
-
|
(130,000
|
)
|
|||||
|
Settlement of interest rate swaps
|
-
|
(3,573
|
)
|
|||||
|
Payment of promissory note
|
-
|
(9,625
|
)
|
|||||
|
Payment of dividends
|
(3,259
|
)
|
(3,056
|
)
|
||||
|
Payments of financing costs
|
-
|
(6,921
|
)
|
|||||
|
Exercise of options
|
504
|
2,071
|
||||||
|
Redemption of options
|
(155
|
)
|
(2,111
|
)
|
||||
|
Redemption of stock units
|
(1,228
|
)
|
-
|
|||||
|
Common stock repurchased
|
(27,032
|
)
|
(20,481
|
)
|
||||
|
Net cash (used in) provided by financing activities
|
$
|
(31,170
|
)
|
$
|
76,304
|
|||
|
Net (decrease) increase in cash
|
$
|
(32,549
|
)
|
$
|
73,624
|
|||
|
Effect of foreign currency translation on cash
|
$
|
(324
|
)
|
$
|
235
|
|||
|
Cash, beginning of period:
|
||||||||
|
Unrestricted
|
128,320
|
41,765
|
||||||
|
Restricted
|
15,155
|
35,074
|
||||||
|
Total cash at beginning of period
|
143,475
|
76,839
|
||||||
|
Cash, end of period:
|
||||||||
|
Unrestricted
|
105,672
|
130,551
|
||||||
|
Restricted
|
4,930
|
20,147
|
||||||
|
Total cash at end of period
|
$
|
110,602
|
$
|
150,698
|
||||
|
Three Months Ended
September 30,
|
||||||||
|
2022
|
2021
|
|||||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
11,536
|
$
|
13,468
|
||||
|
Add:
|
||||||||
|
Interest expense, net
|
4,802
|
5,397
|
||||||
|
Gain on extinguishment of debt
|
-
|
(375
|
)
|
|||||
|
Income tax expense
|
3,797
|
4,073
|
||||||
|
Depreciation expense
|
861
|
767
|
||||||
|
Amortization expense
|
454
|
477
|
||||||
|
EBITDA
|
$
|
21,450
|
$
|
23,807
|
||||
|
Components of Adjusted EBITDA
|
||||||||
|
Corporate restructuring (a)
|
17
|
-
|
||||||
|
ERP/CRM (b)
|
435
|
-
|
||||||
|
Stock options, restricted stock, and incentives expense (c)
|
1,442
|
1,752
|
||||||
|
Transactional expenses (d)
|
-
|
(232
|
)
|
|||||
|
FDA PMTA (e)
|
1,169
|
960
|
||||||
|
Adjusted EBITDA
|
$
|
24,513
|
$
|
26,287
|
||||
|
|
||||||||
| (a) |
Represents costs associated with corporate restructuring, including severance.
|
| (b) |
Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses.
|
| (c) |
Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units.
|
| (d) |
Represents the fees incurred for transaction expenses.
|
| (e) |
Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA").
|
|
Three Months Ended
September 30,
|
||||||||
|
2022
|
2021
|
|||||||
|
GAAP EPS
|
$
|
0.60
|
$
|
0.65
|
||||
|
Gain on extinguishment of debt (a)
|
-
|
(0.01
|
)
|
|||||
|
Corporate restructuring (b)
|
0.00
|
-
|
||||||
|
ERP/CRM (c)
|
0.02
|
-
|
||||||
|
Stock options, restricted stock, and incentives expense (d)
|
0.05
|
0.06
|
||||||
|
Transactional expenses (e)
|
-
|
(0.01
|
)
|
|||||
|
FDA PMTA (f)
|
0.04
|
0.03
|
||||||
|
Tax (expense) benefit (g)
|
0.01
|
0.00
|
||||||
|
Adjusted diluted EPS
|
$
|
0.72
|
$
|
0.72
|
||||
|
Totals may not foot due to rounding
|
||||||||
| (a) |
Represents gain on extinguishment of debt tax effected at the quarterly tax rate.
|
| (b) |
Represents costs associated with corporate restructuring, including severance, tax effected at the quarterly tax rate.
|
| (c) |
Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses tax effected at the quarterly tax rate.
|
| (d) |
Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs tax effected at the quarterly tax rate.
|
| (e) |
Represents the fees incurred for transaction expenses tax effected at the quarterly tax rate.
|
| (f) |
Represents costs associated with applications related to the FDA PMTA tax effected at the quarterly tax rate.
|
| (g) |
Represents adjustment from quarterly tax rate to annual projected tax rate of 23% in 2022 and 2021.
|
|
Consolidated
|
Zig-Zag Products
|
Stoker's Products
|
NewGen Products
|
|||||||||||||||||||||||||||||
|
3rd Quarter
2022
|
3rd Quarter
2021
|
3rd Quarter
2022
|
3rd Quarter
2021
|
3rd Quarter
2022
|
3rd Quarter
2021
|
3rd Quarter
2022
|
3rd Quarter
2021
|
|||||||||||||||||||||||||
|
Net sales
|
$
|
107,802
|
$
|
109,904
|
$
|
52,061
|
$
|
42,234
|
$
|
33,525
|
$
|
30,472
|
$
|
22,216
|
$
|
37,198
|
||||||||||||||||
|
Gross profit
|
$
|
52,712
|
$
|
54,269
|
$
|
28,035
|
$
|
23,703
|
$
|
18,279
|
$
|
17,104
|
$
|
6,398
|
$
|
13,462
|
||||||||||||||||
|
Operating income
|
$
|
19,821
|
$
|
22,375
|
$
|
18,740
|
$
|
17,122
|
$
|
13,653
|
$
|
13,305
|
$
|
142
|
$
|
2,027
|
||||||||||||||||
|
Adjustments:
|
||||||||||||||||||||||||||||||||
|
Corporate restructuring
|
17
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
|
ERP/CRM
|
435
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||||||||||||
|
Transactional expenses
|
-
|
(232
|
)
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||||||||||
|
FDA PMTA
|
1,169
|
960
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
|
Adjusted operating income
|
$
|
21,442
|
$
|
23,103
|
$
|
18,740
|
$
|
17,122
|
$
|
13,653
|
$
|
13,305
|
$
|
142
|
$
|
2,027
|
||||||||||||||||
| 10 |
|
Turning Point Brands, Inc. | www.turningpointbrands.com | [email protected] | 502.774.9238
|